Last reviewed · How we verify
Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Approved treatments
- Enhertu · Daiichi Sankyo
Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells. - Enhertu · Washington D.C. Veterans Affairs Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma treatment landscape brief
- Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma treatment updates RSS
Frequently asked questions about Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
What drugs treat Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma?
Tracked treatments include Enhertu.
What is the treatment for Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma?
Standard treatment for Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma includes Enhertu. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma patent cliff · Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma CI report
- Treatment: Enhertu · Daiichi Sankyo
- Treatment: Enhertu · Washington D.C. Veterans Affairs Medical Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing